Latest News - Oklahoma Society of Clinical Oncology

PFIZER’S XALKORI® (CRIZOTINIB) APPROVED BY FDA FOR ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA IN CHILDREN AND YOUNG ADULTS

Pfizer Inc. (NYSE:PFE) recently announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI® (crizotinib) for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. The safety […]

Read More

U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma

Bristol Myers Squibb (NYSE: BMY) today announced that OPDIVO®(nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX® (cabozantinib) 40 mg once daily tablets was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).1 The approval is […]

Read More

AstraZeneca announces new FDA approval for TAGRISSO®.

The US Food and Drug Administration (FDA) has approved TAGRISSO® (osimertinib) for adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. About the FDA Decision The results from the Phase […]

Read More

Merck announces new FDA approval for KEYTRUDA

KEYTRUDA has received FDA approval, in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express programmed death ligand 1 (PD-L1) [combined positive score (CPS ≥10)] as determined by an FDA-approved test. This indication is approved under accelerated approval based on progression-free survival. Continued […]

Read More

Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy.

SAN CARLOS, Calif., Nov. 10, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new immunotherapy data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, taking place November 9-14, 2020.  Natera will present […]

Read More

Pfizer provides virtual resources to support OSCO members.

Pfizer Pharmaceuticals is offering the following virtual program to OSCO members.  Anyone wishing to attend should RSVP to [email protected] Speaker Topic Program Day/Date Program Start Time   Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA Biosimilars – An Overview for Health Care  Professionals Thursday, November 19, 2020 11:30 AM PT

Read More

PALTOWN and Natera team up to launch COLONTOWN University

PALTOWN Development Foundation today announced its partnership with Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, on the launch of COLONTOWN University (CTU), the first of its kind online learning center for over 5,300 Colorectal Cancer (CRC) patients and caregivers. COLONTOWN University is a secure online platform that hosts training and educational […]

Read More

Natera Announces Prospective Randomized Clinical Trial with Signatera™

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center clinical trial of palbociclib (IBRANCE®), a CDK4/6 inhibitor developed by Pfizer for the treatment of HR-positive, HER2-negative advanced breast cancer when given in combination with an aromatase […]

Read More

Lilly, USA announces Thyroid Cancer Testing Program for thyroid cancer patients.

Lilly’s Thyroid Cancer Testing Program is designed to provide access to molecular testing for appropriate advanced or metastatic medullary thyroid cancer (“MTC”) patients 12 years of age and older who require systemic therapy and advanced or metastatic non-medullary thyroid cancer (“non-MTC”) patients 12 years of age and older who are radioactive iodine-refractory (if radioactive iodine […]

Read More

Medicare Issues Draft Local Coverage Determination for Signatera™

Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring. Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monitoring. Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics […]

Read More